載入...
Phase II trial of trimelamol in refractory ovarian cancer.
Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using t...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group
1991
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1971798/ https://ncbi.nlm.nih.gov/pubmed/1997112 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|